StockData

Mereo BioPharma vs Rallybio

MREO and RLYB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MREO and RLYB compare

Mereo BioPharma is the larger company, worth 2.7 times as much as Rallybio ($219M against $82.3M).

Rallybio scores higher on the StockData Score (10 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMREORLYB
Size and price
Market cap$219M$82.3M
Share price$0.275$15.29
Change, 1 year−84.6%199%
Change, 5 years−85.6%−85.5%
Beta (5Y)2.290.01
Employees3914
StockData Score
Total score110 (better)
Valuation score02 (better)
Growth score00
Performance score02 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–3.4×
P/S–190×
P/B9.2×0.9× (better)
FCF yield−10.1%–
Growth
Revenue growth (TTM)–−35.6%
Profitability
Operating margin–−5581%
Net margin–6177%
Return on equity−76.6%34.5% (better)
Return on invested capital–−718%
Financial health
Debt / equity–0.00
Interest coverage−440.6×–
Current ratio5.2228.87 (better)
Altman Z-score−4.6811.42 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions7.1%–
Held by insiders0.18%72.6%
Insider net buying, 12 months–$4.2M
Superinvestors holding–1
Short interest, % of float–2.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.